A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
OptimizeRx is a leading healthcare technology company that is redefining how life sciences brands connect with patients and healthcare providers. OptimizeRx is a Nevada corporation and was founded in 2006 in Rochester, Michigan as a healthcare technology company delivering various types of messages, including coupons and co-pays directly to physicians and pharmacists though electronic health record (EHR) systems and ePrescribing (eRx) platforms. Over time, the demand for different types of communication and marketing solutions among life sciences organizations, healthcare professionals (HCPs), and patients led us to expand upon our initial solution to increase the variety of health-related information we deliver, as well as the platforms, technology, and audiences through, and to which we deliver. By combining artificial intelligence (AI)-driven tools with our original financial messaging solution, we progressively enhanced our original financial messaging solution.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 110M | 92M | 72M | 62M | 61M | 43M |
| Net Income | 34K | -20M | -18M | -11M | 378K | -2.2M |
| EPS | $0.01 | $-1.10 | $-1.03 | $-0.64 | $0.02 | $-0.15 |
| Free Cash Flow | 12M | 4.8M | -7.3M | 11M | 626K | -6.4M |
| ROIC | 0.1% | -13.6% | -10.9% | -9.1% | 0.3% | -4.4% |
| Gross Margin | 65.3% | 64.5% | 60.0% | 62.4% | 58.1% | 55.7% |
| Debt/Equity | 0.26 | 0.30 | 0.30 | 0.07 | 0.07 | 0.21 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | 6.8M | -14M | -26M | -12M | 361K | -2.1M |
| Operating Margin | 6.2% | -14.9% | -36.9% | -19.7% | 0.6% | -4.9% |
| ROE | 0.0% | -16.5% | -13.9% | -9.1% | 0.3% | -4.4% |
| Shares Outstanding | 19M | 18M | 17M | 18M | 19M | 15M |
OptimizeRx Corp passes 3 of 9 quality checks, indicating weak fundamentals.
OptimizeRx Corp trades at 605.0x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average gross margin is 60.1%. Total shareholder yield (buybacks) is 6.7%.
OptimizeRx Corp (OPRX) has a current P/E ratio of 605.0, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
OptimizeRx Corp (OPRX) has a 5-year average return on invested capital (ROIC) of -7.5%. This is below average and may indicate limited pricing power.
OptimizeRx Corp (OPRX) has a market capitalization of $113M. It is classified as a small-cap stock.
OptimizeRx Corp (OPRX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 6.67%.
Based on historical P/E analysis, OptimizeRx Corp (OPRX) appears expensive. The current P/E of 605.0 is 3933% above its historical median of 15.0.
OptimizeRx Corp (OPRX) operates in the Services-Business Services, Nec industry, within the Industrials sector.
OptimizeRx Corp (OPRX) reported annual revenue of $92 million in its most recent fiscal year, based on SEC EDGAR filings.
OptimizeRx Corp (OPRX) has a net profit margin of -21.8%. The company is currently unprofitable.
OptimizeRx Corp (OPRX) generated $5 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
OptimizeRx Corp (OPRX) has a debt-to-equity ratio of 0.30. This indicates a conservatively financed balance sheet.
OptimizeRx Corp (OPRX) reported earnings per share (EPS) of $-1.10 in its most recent fiscal year.
OptimizeRx Corp (OPRX) has a return on equity (ROE) of -16.5%. A negative ROE may indicate losses or negative equity.
OptimizeRx Corp (OPRX) has a 5-year average gross margin of 60.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for OptimizeRx Corp (OPRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
OptimizeRx Corp (OPRX) has a book value per share of $6.40, based on its most recent annual SEC filing.